Vinge has advised Scandic Hotels Group AB (publ) on a fully underwritten rights issue, which will provide Scandic with issue proceeds amounting up to approximately SEK 1,765 million before deduction of transaction costs, and on the agreement of new credit facilities amounting to SEK 1,400 million.
The board of directors of Hansa Biopharma has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Hansa Biopharma will raise proceeds of SEK 1.1 billion, before issue costs.
Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 185 million in issue proceeds.
Vinge has advised Bergs Timber AB (publ) in connection with the transfer of the sawmills in Orrefors, Vimmerby, Mörlunda and the assets at the already discontinued operations at Gransjö.
The board of directors of Medicover has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Medicover will raise proceeds of SEK 1.5 billion, before issue costs.
Vinge has advised VNV Global in connection with the process of changing the group’s domicile from Bermuda to Sweden (the “Redomestication”). The Redomestication is carried out by way of a scheme of arrangement under Bermuda law, whereby Swedish Depository Receipts in VNV Global Ltd. will be exchanged for shares in the Swedish group entity VNV Global AB (publ) that, following the Redomestication, will constitute the new parent company of the group. The shares of VNV Global AB (publ) will be listed on the main market of Nasdaq Stockholm.
Vinge has advised Nanoform Finland Plc (“Nanoform”) in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden.